about
Tumor necrosis factor alpha inhibitors in patients with Takayasu's arteritis refractory to standard immunosuppressive treatment: cases series and review of the literature.Cryofibrinogenaemia-a neglected disease.Position paper: Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis.Predictors of AA amyloidosis in familial Mediterranean fever.Hyperimmunoglobulinemia E and efficacy of elimination diet in two patients with Schnitzler syndrome.Rituximab as induction therapy in relapsing eosinophilic granulomatosis with polyangiitis: A report of 6 cases.[NODULAR POLYARTERITIS ASSOCIATED WITH HEPATITIS B VIRUS (A CASE STUDY)].[Role of the morphogenetic proteins FGF-23 and Klotho and the glycoprotein sclerostin in the assessment of the risk of cardiovascular diseases and the prognosis of chronic kidney disease].[THE INFLUENCE OF CHRONIC HEPATITIS C ON ATHEROSCLEROSIS PROGRESSION].[Microalbuminuria, a universal marker of unfavourable prognosis][Modern conceptions of cardiac amyloidosis].[Clinical aspects of hypereosinophilia syndrome][Hyperhomocysteinemia and acute phase proteins in various forms of ischemic heart disease][Ischemic renal disease (atherosclerotic renovascular hypertension), a clinical variant of disseminated atherosclerosis and a cause of chronic renal insufficiency].[Cardiorenal syndrome in ischemic renal disease (atherosclerotic renovascular hypertension)][Hypertension combined with atherosclerotic lesions in carotid arteries: should angiotensin converting enzyme inhibitors be prescribed?].Does the revised definition of eosinophilic granulomatosis with polyangiitis (Churg-Strauss) indicate the need for a new treatment? Comment on the article by Puéchal et al.[Use of Tachocomb agent in cardiovascular surgery].HCV-associated cryoglobulinaemic vasculitis: triple/dual antiviral treatment and/or rituximab?[Kidney injury molecules (KIM-1, MCP-1) and type IV collagen in the assessment of activity of antineutrophil cytoplasmic antibody-associated glomerulonephritis].[Apical hypertrophic cardiomyopathy associated with HCV infection].Letter: cure of chronic hepatitis B and D after 12 years of treatment with low-dose standard interferon alfa-2b.Changing patterns of clinical severity and risk of mortality in granulomatosis with polyangiitis over four decades: the Russian experience.[Evolution of the ideas about arterial hypertension in the papers of E.M. Tareev].The role of temporal artery biopsy in patients with giant-cell arteritis is debated.ANCA-associated vasculitis: mission incomplete.Personalized Biologic Therapy for Large Vessel Vasculitis: Comment on the Articles by Langford et al.[Fibromuscular dysplasia of the renal artery as a course of arterial hypertension in a young patient: a successful outcome of invasive treatment][Clinical value of surfactant protein D as a biomarker of pulmonary fibrosis in patients with scleroderma systematica in relation to the presence of gastroesophageal reflux].[IGA-nephropathy with nephrotic syndrome as an extrapulmonary manifestation of sarcoidosis][Left atrium myxoma and fibrosing alveolitis]Giant cell arteritis, infections and biologics.Biologic Therapy for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss): Comment on the Article by Jachiet et al.[Ischemic renal disease: clinical course, prognosis, possibilities of treatment]Five Factor Score in patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss; EGPA): to use or not to use?[Chronic progressive nephropathies and modern lifestyle]Eotaxin-3 as a Biomarker of Activity in Established Eosinophilic Granulomatosis with Polyangiitis.Low aquaporin-2 excretion in the nephrotic syndrome: an escape from the vasopressin regulating effect[Diagnostic and treatment problems in sarcoidosis in the therapist's practice][Modern criteria of sarcoidosis activity and approaches to glucocorticoid therapy]
P50
Q38133360-D1FAF17B-88A4-472C-ABBD-03528B5240B1Q38993203-32F02B8E-6D64-42FF-898C-4AE128387C40Q40041740-661F586A-41FE-4686-BE49-C289711F97C3Q40173923-E405C84B-05A7-4176-93EC-562697613889Q40182876-833C8EB4-BC66-4F03-BEC5-B38658F6723FQ40400418-B9AD2265-3ABE-43BA-9D5D-7A2450607B97Q41191342-E57885CD-BF1E-41FB-BDED-FE47802148FEQ41476278-4C435CAE-4E35-428C-AEB1-361DD279403CQ41635461-DE1B8EAA-9B3E-435B-AA73-FAF8F53C1A69Q44149930-77F1D821-D32B-4157-94F4-0B94BC19D5F7Q44271989-D2EA4C4A-2162-4092-9711-59534DEE014FQ44857958-7DD3FAAD-3561-4138-8A80-6A72FAE8ECF0Q45033258-984C6B20-75BF-44FE-B2A1-B3B200CDD789Q46165276-05CFE26A-6B8F-40FD-83D7-B47319FD94A9Q46354159-F03C3CAF-4B6F-4BF6-BD88-32D3C98B9F08Q46850206-5E06515F-A343-420B-844E-5A7B354A21C9Q49820442-4E0AE57A-4CDC-4003-A77F-B745F26D2867Q50118245-0465F951-C5AA-4EEC-9FDF-52F1294E21D3Q50282822-45803252-95A8-49CB-9153-E065EA6C3BB4Q50519547-E250299F-BAE5-43E2-B274-2172E06CC268Q50556878-1FD9A69B-7640-41C7-ACAB-74CFE855403AQ51579097-7E7E8FED-8E6C-4685-A070-46440EF71723Q51688522-52677889-1BC0-434A-8574-5B5B86FB62BAQ52363590-630CABC9-A1A5-4398-A81B-EC7B1840F89FQ52676518-FAA64D53-6305-4677-AADE-8A6489E23B65Q53226936-62B2B433-879B-4ED5-A296-59BC467FEE8AQ53415506-04F312A5-C3E7-42E8-9736-AA20D42C9F1EQ53439249-37CB5EC3-B607-4EDB-8629-B0D136865FBFQ53486522-0EB78F99-30C9-48FE-B0B1-81A110345DD2Q53575208-7C6DB881-628D-4AEA-B3A9-156339849091Q53575213-AD987206-1F71-452F-A353-D35C186D81E8Q53591677-8262B11B-8791-43B2-B8C0-E44396250A7EQ53623511-3F6592BD-FE30-4520-AD1B-06B570D04A93Q53691268-8D507166-12DD-4030-A1AB-50EEE1D80732Q54541523-E96FB8DC-E2E1-4C70-936C-E286C438F1F5Q54547071-FE186D69-DFA3-4D38-9D42-5C7A9BC1DAB5Q54639894-50EAC1F1-CEDC-4E25-98B8-99576FD0C015Q58544242-F8384248-442C-4A62-9624-BCE104A8F522Q68026485-AB5F9EC2-A9AA-4246-84F6-376AA398A211Q68026489-33735705-E2FC-44AA-B86B-7C48EBD2A0EC
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Sergey Moiseev
@ast
Sergey Moiseev
@en
Sergey Moiseev
@es
Sergey Moiseev
@nl
Sergey Moiseev
@sl
type
label
Sergey Moiseev
@ast
Sergey Moiseev
@en
Sergey Moiseev
@es
Sergey Moiseev
@nl
Sergey Moiseev
@sl
prefLabel
Sergey Moiseev
@ast
Sergey Moiseev
@en
Sergey Moiseev
@es
Sergey Moiseev
@nl
Sergey Moiseev
@sl
P106
P21
P31
P496
0000-0002-7232-4640
P569
2000-01-01T00:00:00Z